Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.
US-based cancer therapy developers Cullinan Oncology and PDI Therapeutics have launched a new company called Cullinan Mica with $26m from a series A round that included Cullinan Oncology itself.
Cullinan Oncology was joined by Avalon Ventures, the venture capital firm that formed PDI in 2015 in partnership with pharmaceutical firm GlaxoSmithKline, as well as Bregua Corporation, and Multiple Myeloma Research Foundation’s Myeloma Investment Fund.
The companies founded Cullinan Mica in order to focus on CLN-619, a monoclonal antibody initially developed…
